Freedom to Heal Act of 2025

S 3346, the Freedom to Heal Act of 2025, creates a new registration process for physicians to administer Schedule I investigational drugs under the federal Right to Try program. It directly affects physicians who wish to treat eligible patients with these experimental drugs by requiring them to apply to the Attorney General with specific documentation, including manufacturer agreements and proof of state compliance. Key provisions include a 45-day approval timeline for applications, limits on drug quantities based on submitted requests, and requirements for secure storage and record-keeping. The bill mandates the Attorney General to issue interim rules within 240 days to implement these registration standards, focusing on preventing diversion while enabling patient access.